ESO-T01 delivers its first four multiple myeloma case reports.
ApexOnco Front Page
Recent articles
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Meanwhile, Tango tries again in PRMT5.
Halda, Accent and Vividion take more projects into phase 1.
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
Opdualag chalks up another failure, this time in the extension of an approved use.
